$1.32
0.84%
Nasdaq, Apr 21, 08:39 pm CET
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Evaxion Biotech A/S - ADR Stock price

$1.31
-0.56 30.00% 1M
-12.24 90.34% 6M
-2.92 69.03% YTD
-19.24 93.63% 1Y
-137.19 99.05% 3Y
-8.69 86.91% 5Y
-8.69 86.91% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.00 0.08%
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Key metrics

Market capitalization $1.84m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 0.56
P/B ratio (TTM) P/B ratio 1.13
Revenue (TTM) Revenue $3.30m
EBIT (operating result TTM) EBIT $-15.10m
Cash position $4.58m
EPS (TTM) EPS $-14.54
P/S forward 0.50
Short interest 0.88%
Show more

Is Evaxion Biotech A/S - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Evaxion Biotech A/S - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

Buy
100%

Financial data from Evaxion Biotech A/S - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.30 3.30
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.89 7.89
26% 26%
239%
- Research and Development Expense 11 11
23% 23%
319%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
38% 38%
-458%
Net Profit -12 -12
53% 53%
-348%

In millions USD.

Don't miss a Thing! We will send you all news about Evaxion Biotech A/S - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evaxion Biotech A/S - ADR Stock News

Neutral
GlobeNewsWire
11 days ago
COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.
Neutral
Seeking Alpha
20 days ago
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Swayampakula Ramakanth - HCW Operator Good day, and thank you for standing by. Welcome to t...
Neutral
GlobeNewsWire
25 days ago
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.
More Evaxion Biotech A/S - ADR News

Company Profile

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Christian Kanstrup
Employees 46
Founded 2008
Website www.evaxion-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today